PLK1 and breast carcinoma: BRCA1-deficient breast cancer cells demonstrated higher PLK1 activity, and PLK1 inhibitors trigger stronger synthetic lethality in BRCA1-deficient breast cancer cells compared with BRCA1-proficient one (García et al., 2020).